2,364 Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by China Universal Asset Management Co. Ltd.

Key Points

• China Universal Asset Management increased its Regeneron stake by 12.1% in the third quarter, purchasing 2,364 shares and bringing its holdings to 21,862 shares valued at approximately $16.4 million.
• Institutional ownership remains substantial at 83.31%, with BlackRock, State Street, Bank of America, Amundi and Legal & General among major holders. Insiders, however, sold 8,093 shares worth about $6.5 million over the past three months.
• Regeneron reported quarterly EPS of $14.29, beating estimates by $4.13, while revenue rose 16.7% year over year to $4.29 billion. Analysts maintain a “Moderate Buy” consensus, with an average price target of $847.90.

China Universal Asset Management Co. Ltd. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,862 shares of the biopharmaceutical company's stock after purchasing an additional 2,364 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $16,408,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. State Street Corp increased its position in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock worth $3,014,621,000 after buying an additional 170,210 shares in the last quarter. Bank of America Corp DE increased its position in Regeneron Pharmaceuticals by 2.8% in the first quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company's stock worth $919,120,000 after buying an additional 32,158 shares in the last quarter. Amundi raised its stake in shares of Regeneron Pharmaceuticals by 27.5% in the first quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company's stock worth $780,210,000 after buying an additional 217,892 shares during the period. Finally, Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $473,872,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,093 shares of company stock worth $6,506,845. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.7%

Shares of REGN stock opened at $818.77 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a fifty day simple moving average of $791.28 and a two-hundred day simple moving average of $737.25. The firm has a market capitalization of $84.30 billion, a PE ratio of 20.87, a PEG ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business's revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Jefferies Financial Group lifted their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 20th. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a "buy" rating in a research note on Wednesday, October 21st. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Finally, Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $847.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.